Combined Factor Xa and platelet inhibition to prevent recurrent events after ACS: the story so far

With an unrestricted educational grant from BAYER HEALTHCARE PHARMACEUTICALS

Summary

This video is offered by BAYER HEALTHCARE PHARMACEUTICALS

Learning Objectives

  • To understand the dual-pathway strategy for secondary prevention after ACS
  • To learn about the value of adding rivaroxaban in addition to dual antiplatelet for secondary prevention after ACS
  • To gain insight into the increasing breadth of oral anticoagulant use in cardiology: the rivaroxaban profile

Presentations available when logged in:

  • Session objectives
  • The added value of Factor Xa inhibition in practice: optimising management of complex ACS cases
  • Session evaluation and key learnings